PET shows effectiveness of gantenerumab for Alzheimer's disease

10/10/2011 | AuntMinnie.com (free registration)

PET with carbon-11-labeled Pittsburgh Compound B showed that treatment with an antibody called gantenerumab can reduce the levels of amyloid-beta plaque in the brains of patients with Alzheimer's disease, according to a Swiss study published in the Archives of Neurology. The reduction in the plaque was directly related to the size of the treatment dose, the researchers said. "Additionally, our findings in the placebo-treated patients support previous reports indicating that amyloid load continues to increase in many patients with mild-to-moderate Alzheimer's disease," the researchers added.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN